David A Bushinsky1, David M Spiegel2, Jinwei Yuan3, Suzette Warren4, Jeanene Fogli5, Pablo E Pergola6. 1. Division of Nephrology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York; david_bushinsky@urmc.rochester.edu. 2. Clinical Development. 3. Biometrics. 4. Clinical Operations. 5. Medical Affairs, Relypsa, Inc., a Vifor Pharma Group Company; and. 6. Renal Associates, PA, San Antonio, Texas.
Abstract
BACKGROUND AND OBJECTIVES: Patiromer is a sodium-free, nonabsorbed, potassium-binding polymer that uses calcium as the counter-exchange ion and is approved for treatment of hyperkalemia. The 4-week TOURMALINE study in patients with hyperkalemia previously demonstrated that patiromer administered once daily reduces serum potassium similarly when given with or without food. We report a prespecified exploratory efficacy analysis as well as a post hoc efficacy and safety analysis of the TOURMALINE study on circulating markers of mineral metabolism. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Adults with hyperkalemia (potassium >5.0 mEq/L) were randomized to once-daily patiromer 8.4 g without/with food for 4 weeks, with doses adjusted to achieve and maintain serum potassium 3.8-5.0 mEq/L. Baseline and week 4 serum and 24-hour urine markers of mineral metabolism are reported for all patients combined (evaluable for efficacy, n=112; evaluable for safety, n=113). P values were calculated using a paired t test for change from baseline, unless otherwise specified. RESULTS:Mean (SD) baseline eGFR was 41±26 ml/min per 1.73 m2. Mean (SD) changes from baseline to week 4 were 0.0±0.5 mg/dl (P=0.78; n=100) for albumin-corrected serum calcium, -0.2±0.2 mg/dl (P<0.001; n=100) for serum magnesium, and -0.1±0.7 mg/dl (P=0.47; n=100) for serum phosphate. Median (quartile 1, quartile 3) changes in 24-hour creatinine-normalized urine calcium and phosphate from baseline to week 4 were 2.5 (-11.5, 23.7) mg/24 h (P=0.10; n=69) and -43.0 (-162.6, 35.7) mg/24 h (P=0.004; n=95), respectively. Median (quartile 1, quartile 3) changes in intact parathyroid hormone and 1,25-dihydroxyvitamin D from baseline to week 4 were -13 (-31, 4) pg/ml (P<0.001; n=97) and -2 (-9, 3) pg/ml (P=0.05; n=96), respectively. There were no changes in fibroblast growth factor-23 or 25-hydroxyvitamin D. In patients (n=16) with baseline serum phosphate >4.8 mg/dL, the mean (SD) changes in serum and 24-hour creatinine-normalized urine phosphate from baseline to Week 4 were -0.6±0.8 mg/dl (n=13) and -149.1±162.6 mg/24hr (n=9), respectively. CONCLUSIONS: Patiromer lowered urine phosphate in all patients, and lowered both serum and urine phosphate in a small subset of patients with hyperphosphatemia. Intact parathyroid hormone and 1,25-dihydroxyvitamin D decreased, with no change in serum calcium.
RCT Entities:
BACKGROUND AND OBJECTIVES: Patiromer is a sodium-free, nonabsorbed, potassium-binding polymer that uses calcium as the counter-exchange ion and is approved for treatment of hyperkalemia. The 4-week TOURMALINE study in patients with hyperkalemia previously demonstrated that patiromer administered once daily reduces serum potassium similarly when given with or without food. We report a prespecified exploratory efficacy analysis as well as a post hoc efficacy and safety analysis of the TOURMALINE study on circulating markers of mineral metabolism. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Adults with hyperkalemia (potassium >5.0 mEq/L) were randomized to once-daily patiromer 8.4 g without/with food for 4 weeks, with doses adjusted to achieve and maintain serum potassium 3.8-5.0 mEq/L. Baseline and week 4 serum and 24-hour urine markers of mineral metabolism are reported for all patients combined (evaluable for efficacy, n=112; evaluable for safety, n=113). P values were calculated using a paired t test for change from baseline, unless otherwise specified. RESULTS: Mean (SD) baseline eGFR was 41±26 ml/min per 1.73 m2. Mean (SD) changes from baseline to week 4 were 0.0±0.5 mg/dl (P=0.78; n=100) for albumin-corrected serum calcium, -0.2±0.2 mg/dl (P<0.001; n=100) for serum magnesium, and -0.1±0.7 mg/dl (P=0.47; n=100) for serum phosphate. Median (quartile 1, quartile 3) changes in 24-hour creatinine-normalized urine calcium and phosphate from baseline to week 4 were 2.5 (-11.5, 23.7) mg/24 h (P=0.10; n=69) and -43.0 (-162.6, 35.7) mg/24 h (P=0.004; n=95), respectively. Median (quartile 1, quartile 3) changes in intact parathyroid hormone and 1,25-dihydroxyvitamin D from baseline to week 4 were -13 (-31, 4) pg/ml (P<0.001; n=97) and -2 (-9, 3) pg/ml (P=0.05; n=96), respectively. There were no changes in fibroblast growth factor-23 or 25-hydroxyvitamin D. In patients (n=16) with baseline serum phosphate >4.8 mg/dL, the mean (SD) changes in serum and 24-hour creatinine-normalized urine phosphate from baseline to Week 4 were -0.6±0.8 mg/dl (n=13) and -149.1±162.6 mg/24hr (n=9), respectively. CONCLUSIONS: Patiromer lowered urine phosphate in all patients, and lowered both serum and urine phosphate in a small subset of patients with hyperphosphatemia. Intact parathyroid hormone and 1,25-dihydroxyvitamin D decreased, with no change in serum calcium.
Authors: Emma J McMahon; Judith D Bauer; Carmel M Hawley; Nicole M Isbel; Michael Stowasser; David W Johnson; Katrina L Campbell Journal: J Am Soc Nephrol Date: 2013-11-07 Impact factor: 10.121
Authors: George L Bakris; Bertram Pitt; Matthew R Weir; Mason W Freeman; Martha R Mayo; Dahlia Garza; Yuri Stasiv; Rezi Zawadzki; Lance Berman; David A Bushinsky Journal: JAMA Date: 2015-07-14 Impact factor: 56.272
Authors: W G Goodman; J Goldin; B D Kuizon; C Yoon; B Gales; D Sider; Y Wang; J Chung; A Emerick; L Greaser; R M Elashoff; I B Salusky Journal: N Engl J Med Date: 2000-05-18 Impact factor: 91.245
Authors: David A Bushinsky; Patrick Rossignol; David M Spiegel; Wade W Benton; Jinwei Yuan; Geoffrey A Block; Christopher S Wilcox; Rajiv Agarwal Journal: Am J Nephrol Date: 2016-10-27 Impact factor: 3.754
Authors: Bertram Pitt; Stefan D Anker; David A Bushinsky; Dalane W Kitzman; Faiez Zannad; I-Zu Huang Journal: Eur Heart J Date: 2011-01-05 Impact factor: 29.983
Authors: Bertram Pitt; George L Bakris; David A Bushinsky; Dahlia Garza; Martha R Mayo; Yuri Stasiv; Heidi Christ-Schmidt; Lance Berman; Matthew R Weir Journal: Eur J Heart Fail Date: 2015-10-12 Impact factor: 15.534
Authors: Rajiv Agarwal; Patrick Rossignol; Jeffrey Budden; Martha R Mayo; Susan Arthur; Bryan Williams; William B White Journal: Kidney360 Date: 2021-01-15